Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients

Abstract

Introduction: Elderly patients comprise a major subgroup of intensive care unit (ICU) patients, and have distinct characteristics, more co-morbidities, and generally higher mortality than nonelderly ICU patients. A recent study showed that anidulafungin was safe and effective for candidemia and other forms of invasive candidiasis (C/IC) in selected populations of ICU patients. A post hoc analysis of this study was performed to evaluate the comparative efficacy of anidulafungin in elderly (age > 65 years) vs. non-elderly (age 2 patients. (Table Presented) Conclusions: Anidulafungin was effective and safe for the treatment of C/IC in ICU patients (greater-than or equal to) 65 years of age, despite their worse overall health status at baseline. However, the higher non-C/IC related mortality among elderly patients during the follow-up period reduced the number of patients considered a treatment success after EOT.